Instrument Inactif

Autres langues OSE Immunotherapeutics OTC Markets

Actions

ORPHF

FR0012127173

Recherche biotechnologique et médicale

Autres langues

28/09	OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
23/09	OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
23/09	OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
21/09	OSE Immunotherapeutics SA(ENXTPA:OSE) dropped from S&P Global BMI Index
09/09	OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
31/08	OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
28/08	OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
19/08	Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
08/07	Half-Year Report on Liquidity Contract with Invest Securities
24/06	OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting
05/06	OSE Immunotherapeutics : 2026 2025 Universal registration document
05/06	OSE Immunotherapeutics SA Auditor Raises 'Going Concern' Doubt
03/06	Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting
03/06	OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
29/05	OSE Immunotherapeutics Secures Up to EUR19 Million Bridge Financing
28/05	OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
22/05	OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
22/05	OSE Immunotherapeutics Reports Positive Topline Results Of TEDOVA Phase 2 Trial With Tedopi In Recurrent Ovarian Cancer
30/04	OSE Immunotherapeutics : 30/04/2026 OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
30/04	OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
27/04	Milano chiude piatta tra stallo Iran e attesa Big Tech, petrolio +3% -3-
27/04	OSE Immunotherapeutics Notes US FDA Orphan Drug Designation for Pegrizeprument in Heart Transplant
27/04	OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
23/04	OSE Immunotherapeutics Announces Presentation Of Tedopi Phase 2 Topline Results In Ovarian Cancer
23/04	OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting